Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-Pazopanib versus Pazopanib-Sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II). Retz, M., Bedke, J., Herrmann, E., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Frank, M., Gschwend, J., 2017. Ann Oncol 28 (Supplement 5)(8450), v295–v329. doi:10.1093/annonc/mdx371 Abstract Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape. Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness,… Weiterlesen Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventinal study NABUCCO. Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhart, S., Harde, J., Marschner, N., 2017. Ann Oncol 28 (Supplement 5)(293P), 97. doi:10.1093/annonc/mdx365… Weiterlesen